Proceedings of the International scientific and practical conference ― Cambridge Science and Education Conference‖ (February 23-25, 2026) / Publisher website: www.naukainfo.com. – Cambridge, United Kingdom, 2026. - 289 p.

227 (n=35), isolated AH (n=22), isolated AS (n=22), and healthy controls (n=21). The results demonstrated that this comorbid condition causes the most severe metabolic shifts, including significant increases in Lp(a) (48.31±2.91 mg/dL), HOMA-IR (2.90±0.07), and HbA1c (5.95±0.04%). Isolated AS was characterized by peak Lp(a) levels (65.95±5.20 mg/dL), while non-HDL-C consistently exceeded the norm across all clinical groups, confirming its role as a universal dyslipidemia marker. Ultimately, the combination of AH and AS produces a synergistic effect of insulin resistance and hyperuricemia, whereas isolated AS is primarily driven by elevated Lp(a), necessitating targeted screening even without classic risk factors. Keywords: arterial hypertension, atherosclerosis, lipoprotein (a), non-HDL-C, insulin resistance, uric acid, residual risk. Introduction. Cardiovascular diseases continue to hold a dubious primacy among the causes of population mortality. At the same time, patients who simultaneously have arterial hypertension (AH) and systemic atherosclerosis (AS) form the category of the highest risk of fatal complications. Although modern pharmacology offers powerful agents, and the control of blood pressure and target values of low-density lipoprotein cholesterol (LDL-C) is becoming increasingly strict, a significant proportion of patients continue to remain in the zone of serious residual risk [1]. Today, cardiological science and preventive medicine focus on the multicomponent nature of this phenomenon. Its foundation is not only the traditional triad of "cholesterol-pressure-smoking", but also more complex metabolic interrelationships. Among them, a significant place is occupied by genetically determined markers, in particular lipoprotein (a) (Lp(a)), as well as parameters reflecting the content of triglyceride-rich lipoproteins — non-high-density lipoprotein cholesterol (non-HDL-C) [2, 3]. The study of these indicators through the prism of metabolic syndrome, where insulin resistance and hyperuricemia act as key links, acquires special clinical significance. If in the past uric acid was considered exclusively a sign of gout, now it